HP
RVMD icon

Harbourvest Partners’s Revolution Medicines RVMD Stock Holding History

Harbourvest Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44,045
Closed -$869K – 69
2022
Q3 		$869K Buy
+44,045
New +$968K 0.28% 41

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harbourvest Partners's RVMD Position: Q4 2022 in Review

Harbourvest Partners sold out of Revolution Medicines (RVMD) in Q4 2022, closing a stake of 44,045 shares — an estimated $869K sold.

Harbourvest Partners first reported a position in RVMD in Q3 2022 and held it in 1 quarter. The position peaked at $869K in Q3 2022. 135 funds tracked by Wall St. Rank hold RVMD as of Q4 2022.

  • Harbourvest Partners reported no remaining Revolution Medicines position as of Q4 2022 after selling out during the quarter.
  • Harbourvest Partners sold 44,045 Revolution Medicines shares in Q4 2022, an estimated $869K.
  • Harbourvest Partners first reported a position in Revolution Medicines in Q3 2022 and held it in 1 quarter.
  • Harbourvest Partners's Revolution Medicines position peaked at $869K in Q3 2022.
  • 135 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2022.

Based on Harbourvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.